Physician profile
Shana E Weiss
NPI 1932149945
$13,564.38
in general payments reported to CMS, 2019-2025
61 companies · $3,285 in 2025
The $3,285 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $1,439 · 2021: $1,466 · 2022: $1,435 · 2023: $2,059 · 2024: $2,549 · 2025: $3,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,843 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.09 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,842.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.09 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,777.80 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,310.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,185.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $813.16 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $784.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.19 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $782.39 | 2019-2025 | Evenity, Prolia, Otezla |
| Axsome Therapeutics, INC. | $607.43 | 2023-2025 | Auvelity |
| Currax Pharmaceuticals LLC | $536.06 | 2020-2025 | Contrave, Nexletol |
| Corcept Therapeutics | $298.13 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $276.22 | 2019-2025 | Fanapt |
| Abbott Laboratories | $267.21 | 2023-2025 | Freestyle Libre 3 |
| Allergan, INC. | $254.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $254.46 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $245.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shana Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.